Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04093167 · ClinicalTrials.gov registry record · Phase 2

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Canadian Cancer Trials Group.

Recruiting
Registry status
Phase 2
Development phase
230
Enrollment target
10
Study locations

NCT04093167 is a Phase 2 study of Lung Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 230 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04093167, a Phase 2 study of Lung Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.

RECRUITING
Registry status
Phase 2
Development phase
230 participants
Enrollment target
10
Study locations

Study Summary

The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.

Conditions Studied

Lung Cancer

Interventions

  • DRUG Pembrolizumab

Study Locations (10)

Ontario

  • Health Sciences North - Greater Sudbury
  • Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
  • Kingston Health Sciences Centre - Kingston
  • Ottawa Hospital Research Institute - Ottawa
  • Algoma District Cancer Program - Sault Ste. Marie
  • University Health Network - Toronto

Illinois

  • The University of Chicago Medical Center - Chicago

Maryland

  • The Sidney Kimmel Comprehensive Cancer Centre - Baltimore

British Columbia

  • BCCA - Vancouver - Vancouver

Quebec

  • The Jewish General Hospital - Montreal

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2020-05-26
Est. Completion 2027-07-30
Phase Phase 2

Sponsor

Canadian Cancer Trials Group

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04093167

The ClinicalTrials.gov registry entry for NCT04093167 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.

NCT04093167 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Ontario, Illinois, Maryland.

Frequently Asked Questions

What is clinical trial NCT04093167 about?

NCT04093167 is a clinical study titled "Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer". The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pe...

What is the current status of trial NCT04093167?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2020-05-26. Estimated completion is 2027-07-30.

What conditions does trial NCT04093167 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT04093167?

The interventions under investigation include: Pembrolizumab (DRUG).

Who is sponsoring clinical trial NCT04093167?

This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04093167 being conducted?

This trial has 10 study locations across Illinois, Maryland, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.